486 related articles for article (PubMed ID: 33089648)
1. COVID-19 in lung transplant recipients: A multicenter study.
Saez-Giménez B; Berastegui C; Barrecheguren M; Revilla-López E; Los Arcos I; Alonso R; Aguilar M; Mora VM; Otero I; Reig JP; Quezada CA; Pérez V; Valle M; Laporta R; Deu M; Sacanell J; Bravo C; Gavalda J; Lopez-Meseguer M; Monforte V
Am J Transplant; 2021 May; 21(5):1816-1824. PubMed ID: 33089648
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
[TBL] [Abstract][Full Text] [Related]
3. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
6. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain.
Loinaz C; Marcacuzco A; Fernández-Ruiz M; Caso O; Cambra F; San Juan R; Justo I; Calvo J; García-Sesma A; Manrique A; Pérez-Jacoiste Asín MA; Folgueira MD; Aguado JM; Lumbreras C
Transpl Infect Dis; 2020 Oct; 22(5):e13372. PubMed ID: 32562561
[TBL] [Abstract][Full Text] [Related]
7. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.
Xia T; Wang Y
Am J Transplant; 2020 Sep; 20(9):2630-2631. PubMed ID: 32400965
[No Abstract] [Full Text] [Related]
9. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
[TBL] [Abstract][Full Text] [Related]
10. Two distinct cases with COVID-19 in kidney transplant recipients.
Kim Y; Kwon O; Paek JH; Park WY; Jin K; Hyun M; Lee JY; Kim HA; Han S
Am J Transplant; 2020 Aug; 20(8):2269-2275. PubMed ID: 32337859
[TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
13. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.
Tan DHS; Chan AK; Jüni P; Tomlinson G; Daneman N; Walmsley S; Muller M; Fowler R; Murthy S; Press N; Cooper C; Lee T; Mazzulli T; McGeer A
Trials; 2021 Mar; 22(1):224. PubMed ID: 33752741
[TBL] [Abstract][Full Text] [Related]
14. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 in lung transplant recipients: A single center case series from New York City.
Aversa M; Benvenuto L; Anderson M; Shah L; Robbins H; Pereira M; Scheffert J; Carroll M; Hum J; Nolan M; Reilly G; Lemaitre P; Stanifer BP; D'Ovidio F; Sonett J; Arcasoy S;
Am J Transplant; 2020 Nov; 20(11):3072-3080. PubMed ID: 32881315
[TBL] [Abstract][Full Text] [Related]
16. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in transplant recipients: The Spanish experience.
Coll E; Fernández-Ruiz M; Sánchez-Álvarez JE; Martínez-Fernández JR; Crespo M; Gayoso J; Bada-Bosch T; Oppenheimer F; Moreso F; López-Oliva MO; Melilli E; Rodríguez-Ferrero ML; Bravo C; Burgos E; Facundo C; Lorenzo I; Yañez Í; Galeano C; Roca A; Cabello M; Gómez-Bueno M; García-Cosío M; Graus J; Lladó L; de Pablo A; Loinaz C; Aguado B; Hernández D; Domínguez-Gil B;
Am J Transplant; 2021 May; 21(5):1825-1837. PubMed ID: 33098200
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
Pereira MR; Mohan S; Cohen DJ; Husain SA; Dube GK; Ratner LE; Arcasoy S; Aversa MM; Benvenuto LJ; Dadhania DM; Kapur S; Dove LM; Brown RS; Rosenblatt RE; Samstein B; Uriel N; Farr MA; Satlin M; Small CB; Walsh TJ; Kodiyanplakkal RP; Miko BA; Aaron JG; Tsapepas DS; Emond JC; Verna EC
Am J Transplant; 2020 Jul; 20(7):1800-1808. PubMed ID: 32330343
[TBL] [Abstract][Full Text] [Related]
19. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
[TBL] [Abstract][Full Text] [Related]
20. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
